FMW Media's New to The Street T.V. announces the 248th T.V.
broadcasting of its national syndicated show, Thursday, October 14,
2021, at 10:30 P.M. P.T. on Fox Business Network, featuring the
following four Companies and their businesses representatives:
1). Hapbee Technologies, Inc.'s (OTCQB: HAPBF)
(TSXV: HAPB) interview with Yona Shtern, CEO.
2). Tonix Pharmaceuticals,
Inc.'s (NASDAQ: TNXP) interview with Mr. Seth Lederman,
CEO.
3). PetVivo Holdings, Inc.'s (NASDAQ: PETV)
interview with Mr. John Lai, CEO & President.
4). GlobeX Data Ltd.'s (OTCQB: SWISF) (CSE: SWIS)
(FRA: GDT) interview with Mr. Alain Ghiai, CEO.
Airing tonight,
Thursday, October
14, 2021, the interview with Yona
Shtern, Chief Executive Officer, Hapbee Technologies, Inc. (OTCQB:
HAPBF) (TSXV: HAPB). Talking in-studio at NASDAQ with New to The
Street T.V.'s Host Jane King, Mr. Shtern gives viewers an overview
of the Hapbee Smart Wearable wellness product. Mr. Shtern gives the
televised audience an overview of the worldwide size of the
wellness marketplace and explains the wellness wearable products in
this marketplace. The unique difference in the Hapbee Smart
Wearable compared to other products is that the Hapbee Smart
Wearable transmits a digital signal into the human brain. He
explains how the human bioreceptors react to these digital
signatures, which he describes as a "song." The Company's wearable
comes downloaded with two digital blends, but the users can
download other digital blends through a subscription offered at the
Company. The molecular signature of compounds like caffeine,
nicotine, CBD, and other relaxing sensations can provide the Smart
Wearable end-users benefits, which don't have the usual side
effects of oral consumption. Jane King gives her personal
experience in using the product and looks forward to sharing more
about her experience on future T.V. interviews as she continues
using Smart Wearable. Yona's comprehensive marketing strategy
explains the business proposition and the expected growth at Hapbee
Technologies, Inc.
New to The Street T.V. airs tonight,
Thursday, October 14, 2021, the interview with Tonix
Pharmaceuticals, Inc.'s (NASDAQ: TNXP) CEO, Seth Lederman. Talking
in-studio at NASDAQ with the "New to The Street" T.V. Host Jane
King, Mr. Lederman explains the Company's recently received FDA
guidance on its TNX-1800. Recently, the Company entered into a
collaboration with Columbia University in New York City, a
scientific relationship that focuses on the COVID-19 immune
responses by both people who recovered from COVID and those who
were asymptomatic to the virus. Seth explains the differences
between a live virus vaccine, which TNXP has in development, and
the worldwide mRNA vaccines. He explains that the TNX-1800, a live
vaccine, disables the COVID virus, limits forward transmissions,
and can be a cheaper vaccine to deploy. Seth talks about the need
for oral anti-viral pharmaceuticals to treat those infected with
COVID-19. He sees clinical solid test results from the combination
of the TNXP's oral product with Remdesivir. Before the interview
concludes, Seth explains their unique relationship with himself,
the Company, and Columbia University. He remains excited about the
scientific outcomes of the recently announced collaborations over
the science of in vitro T-cells for the future of vaccines.
Once again, on tonight's Thursday, October
14, 2021, New to The Street T.V. show welcomes back Mr.
Alain Ghiai, CEO, GlobeX Data, Ltd. (OTCQB: SWISF) (CSE: SWIS)
(FRA: GDT). Alain provides T.V. Host Jan King and viewers an update
about the ever-growing corporate fundamental at GlobeX Data, Ltd.
and its SekurSuite® cybersecurity products for large and small
corporate end-users. Owning their proprietary platform, not using
any open-source codes, and never selling mined data, Alain explains
why the Company continues to grow its subscriber base. The Sekur
product lines provide end-users with private texting and email for
both the sender and the receiver. The uniqueness is that the
receiver is protected even though not a subscriber to SWISF's
services. Alain talks about the upcoming email web-based platform
and the ease of the forthcoming downloadable application, which
should be available by subscription soon, first Q1, 2022. The
billboard ad displays the GlobeX Data's Sekur product on the NASDAQ
building, the largest billboard in Time-Square, New York City, and
other electronic billboards and media displays posted throughout
New York City. Alain explains that, because of their sales and
marketing campaigns, including these interviews on New to The
Street T.V., the Company's revenues are up, the Company's stock
price is up approximately 300% year to date, and the Company has
over 2000 unique monthly subscribers. Forthcoming in 2022, GlobeX
Data expects to launch a proprietary product based on the Sekur
privacy platform as a competitive alternative to open-source ZOOM.
He talks about the most recent "HACK" at Facebook, exposing over
3.8B users' data. As always, Mr. Ghiai explains and emphasizes how
GlobeX Data, Ltd. operates its internet platforms and security
businesses under the country of Switzerland's very tough privacy
laws.
Airing tonight, Thursday, October 14,
2021, on the New to The Street T.V. show, the in-studio
interview at NASDAQ with Mr. John Lai, CEO & President, PetVivo
Holdings, Inc. (NASDAQ: PETV). Talking with T.V.'s Host Jane
King, Mr. Lai gives an overview of the Company's
biomedical devices and its osteoarthritis treatment available to
millions of dogs and horses. A one-time treatment delivered by your
veterinarian, the Spryng™ with OsteoCushion™ Technology injection,
can show positive results for approximately 12 months or longer on
osteoarthritis. Spryng™, classified as a biomedical device, helps
reinforce the articulating cartilage barrier between the bones to
protect the remaining cartilage and bone and improves joint
function. With pet owners willing to spend thousands of dollars for
the well-being of their pets, Mr. Lai explains the humanization
process by pet owners and why he sees this upward trend continuing
in pet care. Further, he highlights the use-of-proceeds of its
capital raise and the Company's recent up-listing to the NASDAQ
Market.
About Hapbee Technologies, Inc. (OTCQB:
HAPBF) (TSXV: HAPB)
Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV:
HAPB) is a wearable magnetic field technology Company that aims to
help people enhance how they feel. Powered by patented ultra-low
radiofrequency energy (ulRFE®) technology, Hapbee delivers
low-power electromagnetic signals designed to produce sensations
such as Happy, Alert, Focus, Relax, and others, available for
purchase at www.Hapbee.com.
About Tonix Pharmaceuticals Holding Corp.
(NASDAQ: TNXP):
Tonix Pharmaceuticals Holding
Corp. (NASDAQ: TNXP) is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring, and
developing small molecules and biologics to treat and prevent human
disease and alleviate suffering. Tonix’s portfolio is primarily
composed of immunology and central nervous system (CNS) product
candidates. Tonix’s immunology portfolio includes a COVID-19
platform of product candidates to prevent and treat COVID-19, treat
Long COVID, and detect functional T cell immunity to COVID-19.
Tonix’s lead vaccine candidate for COVID-19, TNX-18001, is a live
replicating vaccine based on Tonix’s recombinant pox vaccine (RPV)
platform to protect against COVID-19, primarily by eliciting a T
cell response. Tonix reported positive efficacy data from animal
studies of TNX-1800 in the first quarter of 2021 and expects to
start a Phase 1 study in humans in the first half of 2022.
TNX-35002 (sangivamycin) is a small molecule antiviral drug to
treat acute COVID-19 and is in the pre-Investigational New Drug
(IND) stage of development. TNX-102 SL3 (cyclobenzaprine HCl
sublingual tablets) is a small molecule drug being developed to
treat Long COVID, a chronic condition, and is also in the pre-IND
stage. Finally, Tonix is developing TNX-21004, an in
vivo diagnostic to measure the presence of functional T cell
immunity to COVID-19. Tonix intends to initiate a first-in-human
clinical study of TNX-21004 in the fourth quarter of 2021,
pending IND clearance. Tonix’s immunology portfolio also includes
biologics to address immunosuppression, cancer, and autoimmune
diseases. The Company’s CNS portfolio consists of small molecules
and biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL3, is in
mid-Phase 3 development for the management of fibromyalgia
–www.tonixpharma.com. 1TNX-1800 is an investigational new
biologic and has not been approved for any
indication. TNX-1800 is based on TNX-801, live horsepox
virus vaccine for percutaneous administration, which is in
development to protect against smallpox and
monkeypox. 2TNX-3500 is an investigational new drug at the
pre-IND stage of development and has not been approved for
any indication. 3TNX-102 SL is an investigational new
drug and has not been approved for any indication. 4TNX-2100
is an investigational new biologic and has not been approved for
any indication.
About PetVivo Holdings, Inc. (NASDAQ:
PETV): PetVivo, Inc. (NASDAQ: PETV) is based in
Minneapolis, Minnesota. It is an emerging biomedical device company
focused on licensing and commercializing innovative medical devices
for pets or pet therapeutics. PetVivo believes that it can leverage
the investments in the human bio-materials and medical device
industries to commercialize therapeutics to pets in a capital and
time-efficient ways. PetVivo's strategy is to in-license
proprietary products from human medical device companies
specifically for use in pets. A vital component of this strategy is
the accelerated timeline to revenues for veterinary medical
devices, which enter the market much earlier than the more
stringently regulated pharmaceuticals - https://petvivo.com/.
About GlobeX Data, Ltd. (OTCQB: SWISF)
(CSE: SWIS) (FRA: GDT):
GlobeX Data, Ltd. (OTCQB: SWISF) (CSE: SWIS) (FRA:
GDT) is a Cybersecurity and Internet Privacy provider of Swiss
hosted solutions for secure communications and secure data
management. The Company distributes a suite of secure messaging
applications, encrypted emails, secure communications, and secure
data management tools, using Swiss privacy laws, proprietary
technology, and its independent platform, away from big techs
hosting platforms. GlobeX Data Ltd. sells its products through its
approved wholesalers and distributors and telecommunications
companies worldwide. GlobeX Data Ltd. serves consumers, businesses,
and governments worldwide – https://www.globexdata.com. Sekur® is a
Swiss secure communications application offering secure and private
messaging, emails, voice messages, self-deleting messages, and file
transfers from any mobile device, tablet, or desktop. Sekur users
can communicate with Sekur and non-Sekur users through its unique
"Chat-By-Invites" feature and Sekur, send email system. All data
traffic stays in GlobeX Data's Swiss-hosted servers, using its
proprietary HeliX technology, military-grade encryption, and
benefiting from Swiss Privacy Laws – https://sekur.com. Twitter:
@globexdata.
About FMW Media: FMW Media
operates one of the longest-running U.S and International sponsored
and Syndicated Nielsen Rated programming T.V. brands "New to the
Street" and its blockchain show "Exploring The Block." Since 2009,
these brands have run biographical interview segment shows across
major U.S. Television networks. The T.V. platforms reach over 540
million homes both in the U.S. and international markets. FMW
recently added Newsmax to its broadcasting platform, with its first
show broadcasted Sunday, December 27. The NEWSMAX New to The Street
show airs its syndication on Sundays at 10 A.M. EST. FMW is also
one of the nation's largest buyers of linear Television long and
short-form - https://www.newsmaxtv.com/Shows/New-to-the-Street
& https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by the following words: "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "ongoing," "plan," "potential," "predict," "project,"
"should," "will," "would," or the negative of these terms or other
comparable terminology. However, not all forward-looking statements
contain these words. Forward-looking statements are not a guarantee
of future performance or results and will not necessarily be
accurate indications of the times at which such performance or
results are achieved. This press release is considered considering
all Company filings contained in the Edgar Archives of the
Securities and Exchange Commission at www.sec.gov.
FMW Media Contact: Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
And
"New to The Street" Business Development office
Support@NewtoTheStreet.com 1-516-696-5900
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a2cdb10f-8f2b-449c-bc04-e81c7c1eb183
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024